The American Diabetes Association and the European Association for the Study of Diabetes have outlined therapeutic steps for optimal treatment of type 2 diabetes, suggesting that treatment needs to begin or be adjusted when glycosylated hemoglobin (A1C) is ≥7.0% (≥53 mmol/mol), with an ultimate treatment target of <7.0% (<53 mmol/mol).[1] Recommended management considers basal insulin as an essential component of the treatment strategy, and timely initiation of insulin (as basal), when lifestyle changes and metformin therapy fail to control A1C <7.0% (<53 mmol/mol), is an option.[1,2]. Here, INS is linked to type 2 diabetes mellitus.